We are proud to announce that West will be the 1st cancer center in the Mid‑South to offer Daraxonrasib, a next‑generation targeted therapy representing one of the most significant advances in pancreatic cancer treatment in years.
Daraxonrasib is designed to interrupt key cancer‑driving pathways associated with some of the most aggressive forms of pancreatic cancer. Early clinical data has shown meaningful improvements in tumor response, disease control, and survival, thus offering new hope for patients facing a historically difficult‑to‑treat diagnosis.
“This therapy marks a turning point in how we approach pancreatic cancer,” said Dr. Axel Grothey, (Director, GI Oncology Research Chair / Molecular Tumor Board – West Cancer Center). “For decades, treatment options have been limited. Daraxonrasib gives us a powerful new tool – one that may extend survival and improve quality of life for patients who urgently need better treatment options.”
As a nationally recognized leader in cancer research and precision oncology, we are committed to accelerating access to innovative therapies through clinical trials, early‑adoption programs, and multidisciplinary expertise. The introduction of Daraxonrasib reinforces our mission to bring the most advanced cancer care to patients across the Mid-South.
Patients interested in learning more about eligibility for Daraxonrasib or other pancreatic cancer treatment options may contact us at [email protected].